Skip to main content
. 2022 May 19;23(10):5691. doi: 10.3390/ijms23105691

Figure 2.

Figure 2

Evaluation of viability of cells of different glioblastoma cell lines (GSCs—JHH520, NCH644, BTSC233 and non-GSCs—U87) after 72 h of treatment by AE2G3 in comparison with standard-care treatment by temozolomide (TMZ). Asterisk (*) marks the significant difference (p < 0.05) between columns, letter “a” marks significant difference in comparison with non-treated control (NTC).